CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.

CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.

Future Oncol. 2018 Jan 30;:

Authors: Talati C, Lancet JE

Abstract
Multiple novel therapeutic agents against acute myeloid leukemia (AML) have been evaluated in the past several decades without meaningful clinical improvement in outcomes, especially for AML patients age ≥60, where the overall incidence of AML is highest. Therapeutic options mainly consist of hypomethylating agents, ongoing clinical trials and, less commonly, intensive cytotoxic chemotherapy. CPX-351, a novel liposomal formulation which encapsulates cytarabine and daunorubicin in 5:1 molar ratio, has shown promising efficacy, leading to recent US FDA approval for front-line therapy for patients with therapy-related AML and AML with myelodysplasia-related changes based on a large multicenter Phase III clinical trial. This review summarizes the clinical development of CPX-351 as induction therapy.

PMID: 29378418 [PubMed - as supplied by publisher]

from #PM All via ola Kala on Inoreader http://ift.tt/2DQqkcJ